Drug Trial Radar · NCT03376529
Phase 1 Study to Evaluate DDI, PK, Safety, Tolerability of SPR741
Last checked: Nov 20, 2026Latest source record: Jan 5, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
27
Actual
Start
Nov 10, 2017
Primary completion
Dec 19, 2017
Study completion Dec 20, 2017
Sponsor
- Lead sponsor
- Spero TherapeuticsIndustry
- Sponsor type
- Industry
- Collaborators
- Simbec Research; QPS Holdings LLC
- First posted
- Dec 18, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase 1, single-center, multi-arm, open-label, randomized, three-period, crossover study to evaluate the drug-drug interaction, pharmacokinetics, safety, and tolerability of a single dose of SPR741 combined with each of 3 different partner antibiotics (ceftazidime or piperacillin/tazobactam or aztreonam) in healthy volunteers. Participants will be administered single doses of SPR741 alone, a single dose of SPR741 in combination with 1 of 3 different partner antibiotics, and the partner antibiotic alone in a randomized sequence. Twenty-seven (27) adult male and female normal healthy participants 18 to 55 years of age are planned to participate in the study. Women of childbearing potential will not be eligible to participate.
Conditions
- Healthy Volunteers
Interventions
SPR741Drug
400 mg IV over 1 hour
CeftazidimeDrug
1.0 gram IV over 1 hour
Piperacillin/tazobactamDrug
4.5 grams IV over 1 hour
AztreonamDrug
1.0 gram IV over 1 hour
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetics: Maximum concentration (Cmax)Time frame: Days 1 to 2, Days 4 to 5, Days 7 to 8
- Pharmacokinetics: Area under the concentration-time curve from time 0 to last measurable time-point (AUC0-t)Time frame: Days 1 to 2, Days 4 to 5, Days 7 to 8
- Pharmacokinetics: Area under the concentration-time curve from time 0 to infinity (AUC0-inf)Time frame: Days 1 to 2, Days 4 to 5, Days 7 to 8
- Pharmacokinetics: Time to maximum concentration (Tmax)Time frame: Days 1 to 2, Days 4 to 5, Days 7 to 8
- Pharmacokinetics: Terminal Elimination Rate Constant (kel)Time frame: Days 1 to 2, Days 4 to 5, Days 7 to 8
- Pharmacokinetics: Terminal half-life (t1/2)Time frame: Days 1 to 2, Days 4 to 5, Days 7 to 8
- Pharmacokinetics: Terminal clearance (CL)Time frame: Days 1 to 2, Days 4 to 5, Days 7 to 8
- Pharmacokinetics: Volume of distribution (Vd)Time frame: Days 1 to 2, Days 4 to 5, Days 7 to 8
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Simbec Research, Ltd.
Merthyr Tydfil, Mid Glamorgan, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.